open access
Acute/subacutae demyelinating polyneuropathy in Parkinson’s Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report
, 12, 12, 12
Affiliations- Department of Neurology & Stroke, St. Adalbert Hospital, Gdansk, Poland
- Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland
open access
Abstract
Polyneuropathy (PNP) is a known complication of levodopa-carbidopa intestinal gel (LCIG) therapy of advanced Parkinson’s Disease (PD). The overall prevalence of PNP in PD is estimated to be 42.1% (as shown in a review by Romagnolo et al. 2018), and the most common type is chronic axonal polyneuropathy. There is a group of acute/subacute onset demyelinating polyneuropathies, which is far less common, although it seems to be an important factor leading to the rapid discontinuation of LCIG treatment. In this systematic review, we present data on demyelinating polyneuropathy with acute/subacute onset; we identified nine papers including prospective assessments and case reports, with detailed information on 15 patients. In all patients, despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) or plasma exchange (PE), the LCIG therapy was terminated. We also present a case of subacute demyelinating polyneuropathy with effective treatment and continuation of LCIG therapy.
Abstract
Polyneuropathy (PNP) is a known complication of levodopa-carbidopa intestinal gel (LCIG) therapy of advanced Parkinson’s Disease (PD). The overall prevalence of PNP in PD is estimated to be 42.1% (as shown in a review by Romagnolo et al. 2018), and the most common type is chronic axonal polyneuropathy. There is a group of acute/subacute onset demyelinating polyneuropathies, which is far less common, although it seems to be an important factor leading to the rapid discontinuation of LCIG treatment. In this systematic review, we present data on demyelinating polyneuropathy with acute/subacute onset; we identified nine papers including prospective assessments and case reports, with detailed information on 15 patients. In all patients, despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) or plasma exchange (PE), the LCIG therapy was terminated. We also present a case of subacute demyelinating polyneuropathy with effective treatment and continuation of LCIG therapy.
Keywords
Parkinson’s Disease, levodopa/carbidopa intestinal gel, neuropathy, demyelinating polyneuropathy, acute/subacute onset
Supp./Additional Files (1)
About this articleTitle
Acute/subacutae demyelinating polyneuropathy in Parkinson’s Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Review Article
Pages
169-176
Published online
2023-01-11
Page views
2598
Article views/downloads
798
DOI
Pubmed
Bibliographic record
Neurol Neurochir Pol 2023;57(2):169-176.
Keywords
Parkinson’s Disease
levodopa/carbidopa intestinal gel
neuropathy
demyelinating polyneuropathy
acute/subacute onset
Authors
Radosław Piekarski
Anna Roszmann
Jarosław Dulski
Jarosław Sławek
References (41)- Siuda J. Importance of non-motor symptoms in PD and atypical parkinsonism. Neurol Neurochir Pol. 2021; 55(6): 503–507.
- Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord. 2008; 23(13): 1850–1859.
- Szadejko K, Dziewiatowski K, Szabat K, et al. Polyneuropathy in levodopa-treated Parkinson's patients. J Neurol Sci. 2016; 371: 36–41.
- Comi C, Magistrelli L, Oggioni GD, et al. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism Relat Disord. 2014; 20(12): 1329–1334.
- Romagnolo A, Merola A, Artusi CA, et al. Levodopa-Induced neuropathy: a systematic review. Mov Disord Clin Pract. 2019; 6(2): 96–103.
- Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. Mov Disord. 2013; 28(10): 1391–1397.
- Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010; 68(1): 28–36.
- Jugel C, Ehlen F, Taskin B, et al. Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS One. 2013; 8(6): e66639.
- Cáceres-Redondo MT, Carrillo F, Lama MJ, et al. Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. J Neurol. 2014; 261(3): 561–569.
- Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007; 22(8): 1145–1149.
- Galazky I, Schoof J, Stallforth S, et al. Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism Relat Disord. 2014; 20(1): 125–127.
- Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord. 2014; 20(1): 27–31.
- Pintér D, Deli G, Juhász A, et al. Long-term successful treatment of chronic inflammatory demyelinating polyneuropathy-like polyneuropathy induced by levodopa-carbidopa intestinal gel with intravenous immunoglobulin. Eur J Neurol. 2019; 26(12): e96–e97.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.
- Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand. 2014; 129(1): e1–e5.
- Merola A, Romagnolo A, Zibetti M, et al. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016; 23(3): 501–509.
- Kobylecki C, Marshall AG, Gosal D, et al. 114 Subacute axonal and demyelinating peripheral neuropathy complicating Duodopa therapy for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012; 83(3): e1.64–e1.
- Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015; 86(5): 490–495.
- Rivero-de-Aguilar A, Sesar A, Fernandez-Pajarin G, et al. Polirradiculoneuropatia desmielinizante inflamatoria cronica asociada al tratamiento con infusion intraduodenal de levodopa-carbidopa [Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa]. RevNeurol. 2019; 69(7): 304–306.
- Onofrj M, Bonanni L, Cossu G, et al. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Related Disord. 2009; 15: S233–S236.
- Capuano A, Rafaniello C, Potenza S, et al. A signal from the Italian pharmacovigilance database: levodopa/carbidopa and polyneuropathy. Drug Saf. 2010; 33: 935–936.
- Sensi M, Cossu G, Mancini F, et al. Which patients discontinue? Issues on levodopa/carbidopa intestinal gel treatment: italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord. 2017; 38: 90–92.
- Poewe W, Bergmann L, Kukreja P, et al. Levodopa-Carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Parkinsons Dis. 2019; 9(3): 531–541.
- Pauls KA, Toppila J, Koivu M, et al. Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel. Brain Behav. 2021; 11(12): e2408.
- Van den Bergh PYK, Piéret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004; 29(4): 565–574.
- Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15): 2649–2653.
- Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord. 2017; 45: 13–20.
- Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80(1): 101–110.
- Toth C, Suchowersky O, Zochodne D. Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view. Mov Disord. 2010; 25(4): 525.
- Białecka M, Robowski P, Honczarenko K, et al. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. Neurol Neurochir Pol. 2009; 43(3): 272–285.
- Westin J, Nyholm D, Pålhagen S, et al. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol. 2011; 34(2): 61–65.
- Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord. 2013; 19(5): 501–507.
- Nishimoto Y, Odaka M, Hirata K, et al. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004; 148(1–2): 200–205.
- McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987; 110 (Pt 6): 1617–1630.
- Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve. 2009; 39(2): 206–220.
- Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015; 85(6): 498–504.
- Ilyas AA, Mithen FA, Dalakas MC, et al. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 1992; 107(1): 111–121.
- Baskar D, Amalnath D, Mandal J, et al. Antibodies to Zika virus, and gangliosides in Guillain-Barre syndrome: A prospective single-center study from southern India. Neurol India. 2018; 66(5): 1324–1331.
- Kalita J, Chandra S, Bhoi SK, et al. Clinical, nerve conduction and nerve biopsy study in vitamin B12 deficiency neurological syndrome with a short-term follow-up. Nutr Neurosci. 2014; 17(4): 156–163.
- Roos D. Neurological complications in patients with impaired vitamin B12 absorption following partial gastrectomy. Acta Neurol Scand Suppl. 1978; 69: 1–77.
- Saperstein DS, Wolfe GI, Gronseth GS, et al. Challenges in the identification of cobalamin-deficiency polyneuropathy. Arch Neurol. 2003; 60(9): 1296–1301.
